A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice
暂无分享,去创建一个
Yin Zhang | Richard Ballweg | Guan-Sheng Liu | Alan Ashbaugh | Joseph Facciolo | Melanie T. Cushion | Tongli Zhang
[1] Hui Qu,et al. Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis , 2017, Oncotarget.
[2] Francisco Antunes,et al. Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice , 2013, PloS one.
[3] F. Schluenzen,et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria , 2001, Nature.
[4] Melanie T. Cushion,et al. Echinocandin Treatment of Pneumocystis Pneumonia in Rodent Models Depletes Cysts Leaving Trophic Burdens That Cannot Transmit the Infection , 2010, PloS one.
[5] Jacques Bille,et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. , 2003, The Journal of infectious diseases.
[6] Jacques Bille,et al. Pneumocystis jirovecii Dihydrofolate Reductase Polymorphisms Associated with Failure of Prophylaxis , 2003, The Journal of eukaryotic microbiology.
[7] Marco Pagni,et al. Identification and Functional Ascertainment of the Pneumocystis jirovecii Potential Drug Targets Gsc1 and Kre6 Involved in Glucan Synthesis , 2017, The Journal of eukaryotic microbiology.
[8] Adithya Cattamanchi,et al. HIV-associated Pneumocystis pneumonia. , 2011, Proceedings of the American Thoracic Society.
[9] Raoul Herbrecht,et al. Caspofungin: the first representative of a new antifungal class. , 2003, The Journal of antimicrobial chemotherapy.
[10] M. Pfaller,et al. In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model , 2007, Antimicrobial Agents and Chemotherapy.
[11] Tarek A. Leil,et al. Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..
[12] I. Macreadie,et al. Isolation of the Pneumocystis carinii dihydrofolate synthase gene and functional complementation in Saccharomyces cerevisiae. , 2006, FEMS microbiology letters.
[13] Tarek A. Leil,et al. Editorial: The emerging discipline of quantitative systems pharmacology , 2015, Front. Pharmacol..
[14] J. Castro,et al. Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. , 2010, HIV/AIDS.
[15] Naimish Patel,et al. Pneumocystis jiroveci Pneumonia in Adult Patients with AIDS , 2004, Treatments in respiratory medicine.
[16] Paul G. Ambrose,et al. Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters , 2017, Antimicrobial Agents and Chemotherapy.
[17] A. Sinai,et al. The 12th International Workshops on Opportunistic Protists (IWOP‐12) , 2013, The Journal of eukaryotic microbiology.
[18] George L. Drusano,et al. Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis , 2006, Antimicrobial Agents and Chemotherapy.
[19] W. Foye,et al. Foye's Principles of Medicinal Chemistry , 2002 .
[20] Ola Sköld,et al. Sulfonamide resistance: mechanisms and trends. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[21] R J Artymowicz,et al. Atovaquone: a new antipneumocystis agent. , 1993, Clinical pharmacy.
[22] Dennis Schmatz,et al. Efficacy of MK-991 (L-743,872), a Semisynthetic Pneumocandin, in Murine Models ofPneumocystis carinii , 1998, Antimicrobial Agents and Chemotherapy.
[23] Ulrika S H Simonsson,et al. A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro , 2015, The Journal of antimicrobial chemotherapy.
[24] Patrick Taffé,et al. Pneumocystis jirovecii Genotype Associated with Increased Death Rate of HIV-infected Patients with Pneumonia , 2013, Emerging infectious diseases.
[25] Andrew H. Limper,et al. Evidence for a Melanin Cell Wall Component in Pneumocystis carinii , 2003, Infection and Immunity.
[26] Melanie T. Cushion,et al. Pneumocystis Workshop: 10th Anniversary Summary , 2009, Eukaryotic Cell.
[27] Oleg Demin,et al. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.
[28] L. Weiss,et al. The 13th International Workshops on Opportunistic Protists (IWOP13) , 2015, The Journal of eukaryotic microbiology.
[29] M. Pfaller,et al. In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species , 2010, Antimicrobial Agents and Chemotherapy.
[30] M. Cushion,et al. In Vitro Selection and In Vivo Efficacy of Piperazine- and Alkanediamide-Linked Bisbenzamidines against Pneumocystis Pneumonia in Mice , 2006, Antimicrobial Agents and Chemotherapy.
[31] Jacques Bille,et al. Mutations of Pneumocystis jirovecii Dihydrofolate Reductase Associated with Failure of Prophylaxis , 2004, Antimicrobial Agents and Chemotherapy.
[32] Brad Reisfeld,et al. A Physiologically Based Pharmacokinetic Model of Rifampin in Mice , 2013, Antimicrobial Agents and Chemotherapy.
[33] Kristina Crothers,et al. Dihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance , 2004, Emerging infectious diseases.
[34] F Leitner,et al. Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim , 1985, Antimicrobial Agents and Chemotherapy.
[35] Yaning Wang,et al. Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004–2006 , 2008, Journal of clinical pharmacology.
[36] Michael A. Lyons,et al. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model , 2015, Journal of Pharmacokinetics and Pharmacodynamics.
[37] Michael A. Lyons,et al. Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[38] Mark G Thomas,et al. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients , 2009, Scandinavian journal of infectious diseases.
[39] Hsin-Yun Sun,et al. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review , 2017, Expert review of anti-infective therapy.
[40] V. Chelliah,et al. The promises of quantitative systems pharmacology modelling for drug development , 2016, Computational and structural biotechnology journal.
[41] Andrew J Copas,et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] Ana Espinel-Ingroff,et al. Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). , 2009, Revista iberoamericana de micologia.
[43] MC Peterson,et al. FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.
[44] H Kropp,et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872) , 1997, Antimicrobial agents and chemotherapy.